Home › Zacks Investment Research Reaffirms "Buy" Rating for OncoGenex Pharmaceuticals Inc
 

Keywords :   


Zacks Investment Research Reaffirms "Buy" Rating for OncoGenex Pharmaceuticals Inc

2016-02-01 10:16:39| Biotech - Topix.net

's stock had its "buy" rating restated by Zacks Investment Research in a report released on Sunday, AnalystRatingsNetwork.com reports. They currently have a $0.75 target price on the biopharmaceutical company's stock.

Tags: inc buy research rating

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Easing US inflation stokes interest rate cut debate
15.05Free From Skincare Award Finalists Announced
15.05Sub-postmasters are self-indulgent, said PO exec
15.05Axalta Hosting Strategy Day; Outlining Three-Year Plan for Accelerating Performance
15.05Pork has its place in healthy, sustainable global diets
15.05BASF Paves the Way for Young Painters at WorldSkills Finals Lyon 2024
15.05Orchard Custom Beauty to Showcase New Product Concepts at PLMA World of Private Label in Amsterdam
15.05Sontara Offers Sri Flo Wipes
More »